Literature DB >> 21029541

Importation of dengue virus type 3 to Japan from Tanzania and Cote d'Ivoire.

Meng Ling Moi1, Tomohiko Takasaki, Akira Kotaki, Shigeru Tajima, Chang-Kweng Lim, Mitsuo Sakamoto, Hajime Iwagoe, Kenichiro Kobayashi, Ichiro Kurane.   

Abstract

Travelers can introduce viruses from disease-endemic to non-disease-endemic areas. Serologic and virologic tests confirmed dengue virus infections in 3 travelers returning to Japan: 2 from Tanzania and 1 from Cote d'Ivoire. Phylogenetic analysis of the envelope gene showed that 2 genetically related virus isolates belonged to dengue virus type 3 genotype III.

Entities:  

Mesh:

Year:  2010        PMID: 21029541      PMCID: PMC3294538          DOI: 10.3201/eid1611.101061

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Dengue virus (DENV) is an arthropod-borne virus that infects ≈100 million persons each year in Southeast Asia, Central and South America, and Africa. Infection with any 1 of the 4 DENV serotypes causes a wide range of disease, from dengue fever to the more severe dengue hemorrhagic fever. Epidemics of dengue-like illness have occurred in Africa, but information about etiology is limited (). Transmission of another arthropod-borne virus, chikungunya virus, which causes disease similar to dengue, has been documented in Tanzania. Although Tanzania is on the list of countries at risk for DENV transmission (), to our knowledge, no DENV isolates have yet been identified and studied there. In Japan as of June 16, 2010, a total of 50 cases of imported dengue had been reported. Among these cases, 2 were dengue fever that had developed in 2 travelers after they returned from Tanzania. We report the molecular characterization of 2 DENV type 3 (DENV-3) isolates from 1 of the travelers who had visited Tanzania in 2010 and from a traveler who had visited Côte d’Ivoire in 2008.

The Study

In 2010, a 55-year-old man (patient 1) and a 23-year-old woman (patient 2) returned to Japan from Tanzania; high fever and thrombocytopenia developed in each on days 1 and 3 days after return, respectively. In 2008, a 65-year-old man (patient 3) returned to Japan from Côte d’Ivoire and subsequently experienced high fever. Serum samples from each of the 3 patients were sent to the National Institute of Infectious Diseases, Japan, for laboratory examination. DENV serotypes were determined by serotype-specific reverse transcription–PCR (RT-PCR) (). DENV-specific immunoglobulin (Ig) M was detected by Dengue Fever Virus IgM Capture ELISA (Focus Diagnostics, Inc., Cypress, CA, USA) used according to the manufacturer’s instructions. Dengue IgG Indirect ELISA (Panbio Ltd, Sinnamon Park, Queensland, Australia) was used to detect anti-DENV IgG according to the manufacturer’s instructions. Serum from patient 1 was negative for anti-DENV IgM and anti-DENV IgG; serum from patients 2 and 3 was positive for anti-DENV IgM and IgG. All 3 serum samples had positive DENV nonstructural protein (NS) 1 antigen results according to NS1 capture ELISA (Platelia Dengue NS1 Antigen assay; Bio-Rad Laboratories, Marnes-la-Coquette, France) and negative chikungunya viral RNA results by RT-PCR. DENV-3 (D3/Hu/Tanzania/NIID08/2010) was isolated from patient 1, and DENV-3 (D3/Hu/Côte d’Ivoire/NIID48/2008) was isolated from patient 3 by using the Aedes albopictus mosquito cell line C6/36 and FcγR-expressing baby hamster kidney cells (). DENV-3 RNA was detected in serum from patient 2 by RT-PCR, but the virus was not isolated. The viral RNA was extracted by using a High Pure Viral RNA Extraction kit (Roche Diagnostics, Mannheim, Germany), transcribed to cDNA, amplified by PCR, and sequenced as described (). Nucleotide sequences of the isolates were compared with selected sequences of DENV-3 (Table). Sequence alignment and phylogenetic analysis was performed by the Genetyx analysis program (Genetyx Corp., Tokyo, Japan). The phylogenetic tree was constructed by using the neighbor-joining method. The selected DENV-3 strains were grouped into 5 genotypes (). Confidence values for virus groupings were assessed by bootstrap assembling analysis of 1,000 replicates. The 2 DENV-3 isolates belonged to DENV-3 genotype III (Figure). The envelope (E)-protein sequence showed that the DENV-3 (D3/Hu/Tanzania/NIID08/2010 strain) isolated from patient 1 had a sequence homology of 98% to the DENV-3 D3/Hu/Côte d’Ivoire/NIID48/2008 strain and 99% to a DENV-3 6805 strain isolated in Saudi Arabia in 2004 (GenBank accession no. AM746229) ().
Table

Comparison of dengue virus type 3 sequences from travelers returning from Tanzania and Côte d’Ivoire with selected dengue virus type 3 sequences*

Year isolatedNameStrainIsolate originGenBank accession no.
2010Tanzania2010D3/Hu/Tanzania/NIID08/2010TanzaniaAB549332
2008Côte d’Ivoire2008–1D3/Hu/Côte d'Ivoire/NIID48/2008Côte d’IvoireAB447989
2008Côte d’Ivoire2008–22008/00510Côte d’IvoireFM213456
2007Bhutan2007–1SV0786_07BhutanFJ606712
2007Bhutan2007–2SV0837_07BhutanFJ606708
2004Saudi Arabia2004–16805Saudi ArabiaAM746229
2004Saudi Arabia2004–26475Saudi ArabiaAM746232
2004Colombia200422379_MEDELLIN/04ColombiaFJ389910
2003India2003GWL-25IndiaAY770511
2001Venezuela2001LARD6667VenezuelaAY146773
2000Brazil200068784BrazilAY038605
2000Venezuela2000LARD6315VenezuelaAY146767
2000Cambodia–India2000†00–28–1HuNIIDCambodia/IndiaAB111081
1997Thailand1997D97–0106ThailandAY145728
1995Honduras1995HN179HondurasFJ189469
1992–1994Malaysia1992–1994–1LN1746MalaysiaAF147458
1992–1994Malaysia1992–1994–2LN2632MalaysiaAF147459
1992Fiji199229472FijiL11422
1991Sri Lanka19912783Sri LankaL11438
1990Sri Lanka1990SK698Sri LankaFJ189449
1989Tahiti19892167TahitiL11619
1989Sri Lanka1989260698Sri LankaL11437
1986Thailand1986D86–007ThailandL11441
1985Mozambique19851559MozambiqueL11430
1984India19841416IndiaL11424
1983Philippines1983168.AP-2PhilippinesL11432
1981Malaysia198129586MalaysiaL11427
1963Puerto Rico1963–1PR6Puerto RicoL11433
1963Puerto Rico1963–2BS-PRico63Puerto RicoAY146762
1956Philippines1956H87PhilippinesL11423
2001DENV-101–44–1HuNIIDTahitiAB111070
2005DENV-2D2/Hu/OPD030NIID/2005East TimorAB219135
2001DENV-4MY01–22713MalaysiaAJ428556

*DENV, dengue virus.
†Strain 00–28–1HuNIID was isolated from a traveler who returned to Japan after visiting Cambodia and India.

Figure

Phylogenetic tree based on the envelope genome sequence of selected dengue virus type 3 (DENV-3) strains. The tree was rooted to DENV-1, DENV-2 and DENV-4. Multiple sequence alignments were performed, and the tree was constructed by using the neighbor-joining method. The percentage of successful bootstrap replication is indicated at the nodes. DENV-3 genotypes are indicated on the right. The isolated DENV-3 strains, D3/Hu/Tanzania/NIID08/2010 strain (Tanzania2010) and D3/Hu/Côte d'Ivoire/NIID48/2008 strain (Côte d’Ivoire2008), are indicated with arrowheads. Scale bar indicates nucleotide substitutions per site.

*DENV, dengue virus.
†Strain 00–28–1HuNIID was isolated from a traveler who returned to Japan after visiting Cambodia and India. Phylogenetic tree based on the envelope genome sequence of selected dengue virus type 3 (DENV-3) strains. The tree was rooted to DENV-1, DENV-2 and DENV-4. Multiple sequence alignments were performed, and the tree was constructed by using the neighbor-joining method. The percentage of successful bootstrap replication is indicated at the nodes. DENV-3 genotypes are indicated on the right. The isolated DENV-3 strains, D3/Hu/Tanzania/NIID08/2010 strain (Tanzania2010) and D3/Hu/Côte d'Ivoire/NIID48/2008 strain (Côte d’Ivoire2008), are indicated with arrowheads. Scale bar indicates nucleotide substitutions per site.

Conclusions

DENV transmission has occurred in western Africa and some parts of eastern Africa (–). We isolated DENV-3 from 2 patients in Japan in whom dengue fever developed after they returned from Côte d’Ivoire (western Africa) and Tanzania (eastern Africa). Detection of DENV-3 in patients 1 and 2 suggests local DENV-3 transmission in Tanzania. As of April 2010, at least 17 suspected cases of dengue have been reported among residents of Dar es Salaam, Tanzania, but the molecular epidemiology of DENV in Tanzania has not been analyzed (). In the absence of such analyses, data on molecular epidemiology of DENV isolated from returning travelers offers timely information to countries where dengue surveillance is not routinely performed. Data and reports of the presence of a competent DENV vector, Ae. aegypti mosquitoes, suggest the need for further studies on local DENV transmission in Tanzania (). It is assumed that travelers increase the risk for introduction of DENV serotypes or strains from disease-endemic to non–disease-endemic areas where competent vectors such as Ae. aegypti or Ae. albopictus mosquitoes are present. The sequence homology among the DENV-3 strain isolated from the traveler to Tanzania (patient 1), the DENV-3 strain isolated from the traveler from Côte d’Ivoire in 2008 (patient 3), and a DENV-3 strain isolated in Saudi Arabia in 2004 ranged from 98% to 99% (GenBank accession nos. AB549332, AB447989, AM746229, respectively). Because the E-protein gene of the isolate from Tanzania was highly similar to those in viruses circulating regionally and the Middle East, the disease could have been introduced or reintroduced into the country from neighboring areas. These data suggest the need for further studies of the route of disease dissemination and surveillance of dengue in Africa. Genetic differences among subtypes may result in differences in virus virulence and epidemic potential (). DENV-3 genotype III, previously isolated from several parts of Africa, Latin America, and the Indian subcontinent, has been associated with higher incidence of major epidemics of dengue and dengue hemorrhagic fever (). The DENV isolates from Tanzania and Côte d’ Ivoire were closely related to a DENV-3 genotype III strain isolated from a major DENV outbreak in northern India in 2003–2004; the E-protein gene homology was 98% (). Emergence of DENV-3 genotype III in geographically diverse areas may thus result from higher epidemic potential of the virus, although further studies are needed to understand the clinical and epidemiologic implications of emergence or reemergence of the virus in Tanzania and Côte d’ Ivoire. Whereas other vector-borne diseases such as malaria and yellow fever have been well studied in Africa, dengue needs more attention with regard to identification of epidemics, clinical implications, and disease management.
  11 in total

1.  Dengue type 3 virus infections in European travellers returning from the Comoros and Zanzibar, February-April 2010.

Authors:  P Gautret; F Simon; H Hervius Askling; O Bouchaud; I Leparc-Goffart; L Ninove; P Parola
Journal:  Euro Surveill       Date:  2010-04-15

2.  Phylogeny of dengue viruses circulating in Jeddah, Saudi Arabia: 1994 to 2006.

Authors:  Ali Zaki; David Perera; Shahrina Shan Jahan; Mary Jane Cardosa
Journal:  Trop Med Int Health       Date:  2008-02-01       Impact factor: 2.622

3.  Molecular evolution and epidemiology of dengue-3 viruses.

Authors:  R S Lanciotti; J G Lewis; D J Gubler; D W Trent
Journal:  J Gen Virol       Date:  1994-01       Impact factor: 3.891

4.  Development of an antibody-dependent enhancement assay for dengue virus using stable BHK-21 cell lines expressing Fc gammaRIIA.

Authors:  Meng Ling Moi; Chang-Kweng Lim; Akira Kotaki; Tomohiko Takasaki; Ichiro Kurane
Journal:  J Virol Methods       Date:  2009-09-23       Impact factor: 2.014

5.  Dengue 3 virus transmission in Africa.

Authors:  D J Gubler; G E Sather; G Kuno; J R Cabral
Journal:  Am J Trop Med Hyg       Date:  1986-11       Impact factor: 2.345

6.  Seasonal changes in the larval populations of Aedes aegypti in two biotopes in Dar es Salaam, Tanzania.

Authors:  M Trpis
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

7.  Extinction and rapid emergence of strains of dengue 3 virus during an interepidemic period.

Authors:  V Wittke; T E Robb; H M Thu; A Nisalak; S Nimmannitya; S Kalayanrooj; D W Vaughn; T P Endy; E C Holmes; J G Aaskov
Journal:  Virology       Date:  2002-09-15       Impact factor: 3.616

8.  Reemergence of dengue virus type-3 (subtype-III) in India: implications for increased incidence of DHF & DSS.

Authors:  Paban Kumar Dash; Man Mohan Parida; Parag Saxena; Ajay Abhyankar; C P Singh; K N Tewari; Asha Mukul Jana; K Sekhar; P V Lakshmana Rao
Journal:  Virol J       Date:  2006-07-06       Impact factor: 4.099

9.  Dengue virus type 3 infection in traveler returning from west Africa.

Authors:  Laetitia Ninove; Philippe Parola; Cécile Baronti; Xavier De Lamballerie; Philippe Gautret; Barbara Doudier; Rémi N Charrel
Journal:  Emerg Infect Dis       Date:  2009-11       Impact factor: 6.883

10.  Emergence and global spread of a dengue serotype 3, subtype III virus.

Authors:  William B Messer; Duane J Gubler; Eva Harris; Kamalanayani Sivananthan; Aravinda M de Silva
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

View more
  22 in total

1.  Chikungunya and dengue fever among hospitalized febrile patients in northern Tanzania.

Authors:  Julian T Hertz; O Michael Munishi; Eng Eong Ooi; Shiqin Howe; Wen Yan Lim; Angelia Chow; Anne B Morrissey; John A Bartlett; Jecinta J Onyango; Venance P Maro; Grace D Kinabo; Wilbrod Saganda; Duane J Gubler; John A Crump
Journal:  Am J Trop Med Hyg       Date:  2012-01       Impact factor: 2.345

2.  Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells.

Authors:  Meng Ling Moi; Chang-Kweng Lim; Kaw Bing Chua; Tomohiko Takasaki; Ichiro Kurane
Journal:  PLoS Negl Trop Dis       Date:  2012-02-28

Review 3.  Dengue--quo tu et quo vadis?

Authors:  Rubing Chen; Nikos Vasilakis
Journal:  Viruses       Date:  2011-09-01       Impact factor: 5.048

4.  Autochthonous spread of DENV-3 genotype III in Malaysia mitigated by pre-existing homotypic and heterotypic immunity.

Authors:  K K Tan; S Nellis; N I Zulkifle; S Sulaiman; S AbuBakar
Journal:  Epidemiol Infect       Date:  2018-06-04       Impact factor: 4.434

5.  Community knowledge and attitudes and health workers' practices regarding non-malaria febrile illnesses in eastern Tanzania.

Authors:  Beatrice Chipwaza; Joseph P Mugasa; Iddy Mayumana; Mbaraka Amuri; Christina Makungu; Paul S Gwakisa
Journal:  PLoS Negl Trop Dis       Date:  2014-05-22

6.  Dengue expansion in Africa-not recognized or not happening?

Authors:  Thomas Jaenisch; Thomas Junghanss; Bridget Wills; Oliver J Brady; Isabella Eckerle; Andrew Farlow; Simon I Hay; Philip J McCall; Jane P Messina; Victor Ofula; Amadou A Sall; Anavaj Sakuntabhai; Raman Velayudhan; G R William Wint; Herve Zeller; Harold S Margolis; Osman Sankoh
Journal:  Emerg Infect Dis       Date:  2014-10       Impact factor: 6.883

7.  Dengue virus serotype 3 infection in traveler returning from West Africa to Germany.

Authors:  Isabella Eckerle; Annette Kapaun; Thomas Junghanss; Paul Schnitzler; Christian Drosten; Thomas Jänisch
Journal:  Emerg Infect Dis       Date:  2015-01       Impact factor: 6.883

8.  Circulation of dengue serotype 1 viruses during the 2019 outbreak in Dar es Salaam, Tanzania.

Authors:  Gaspary O Mwanyika; Leonard E G Mboera; Sima Rugarabamu; Mariam Makange; Calvin Sindato; Julius J Lutwama; Janusz T Paweska; Gerald Misinzo
Journal:  Pathog Glob Health       Date:  2021-04-02       Impact factor: 2.894

9.  Genetic variation in the 3' untranslated region of dengue virus serotype 3 strains isolated from mosquitoes and humans in Brazil.

Authors:  Márcia Gonçalves de Castro; Fernanda Bruycker de Nogueira; Rita Maria Ribeiro Nogueira; Ricardo Lourenço-de-Oliveira; Flávia Barreto dos Santos
Journal:  Virol J       Date:  2013-01-02       Impact factor: 4.099

10.  IgG against dengue virus in healthy blood donors, Zanzibar, Tanzania.

Authors:  Francesco Vairo; Emanuele Nicastri; Salma Masauni Yussuf; Angela Cannas; Silvia Meschi; Mwanakheir A A Mahmoud; Azza H Mohamed; Paul Mohamed Maiko; Pasquale De Nardo; Nazario Bevilacqua; Concetta Castilletti; Antonino Di Caro; Vincenzo Racalbuto; Giuseppe Ippolito
Journal:  Emerg Infect Dis       Date:  2014-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.